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Abstract
Sporadic amyotrophic lateral sclerosis (sALS) is the most common form of ALS, however, the molecular mechanisms 
underlying cellular damage and motor neuron degeneration remain elusive. To identify molecular signatures of sALS we 
performed genome-wide expression profiling in laser capture microdissection-enriched surviving motor neurons (MNs) 
from lumbar spinal cords of sALS patients with rostral onset and caudal progression. After correcting for immunological 
background, we discover a highly specific gene expression signature for sALS that is associated with phosphorylated TDP-
43 (pTDP-43) pathology. Transcriptome–pathology correlation identified casein kinase 1ε (CSNK1E) mRNA as tightly 
correlated to levels of pTDP-43 in sALS patients. Enhanced crosslinking and immunoprecipitation in human sALS patient- 
and healthy control-derived frontal cortex, revealed that TDP-43 binds directly to and regulates the expression of CSNK1E 
mRNA. Additionally, we were able to show that pTDP-43 itself binds RNA. CK1E, the protein product of CSNK1E, in turn 
interacts with TDP-43 and promotes cytoplasmic accumulation of pTDP-43 in human stem-cell-derived MNs. Pathological 
TDP-43 phosphorylation is therefore, reciprocally regulated by CK1E activity and TDP-43 RNA binding. Our framework of 
transcriptome–pathology correlations identifies candidate genes with relevance to novel mechanisms of neurodegeneration.
Keywords ALS · Neurodegeneration · Laser capture microdissection · RNA-seq · RNA · Gene-expression · TDP-43 · 
Casein kinase · Motor neuron · Sporadic disease
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurological dis-
ease characterized by progressive degeneration of upper 
motor neurons (UMNs) and lower motor neurons (LMNs) 
progressing over time to fatal respiratory failure usually in 
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three to 5 years [8, 26]. While about ten percent occur in a 
Mendelian pattern of inheritance (familial ALS, fALS), the 
majority of ALS cases (90%) are sporadic (sALS) with no 
known genetic cause. The etiology of sALS and the mecha-
nisms underlying neurodegeneration remain elusive [47]. 
At present, there is no cure for ALS, a dearth of effective 
therapeutic targets, and no broadly used molecular biomark-
ers to evaluate therapeutic efficacy. Furthermore, there are 
currently no available animal models for experimentation 
in the pathophysiology of sALS. However, several lines of 
evidence implicate a central role for perturbed RNA homeo-
stasis in both fALS and sALS [29]. (1) Neuronal inclusions 
containing hyperphosphorylated Trans-Activation Response 
DNA Binding Protein 43kd (TDP-43) are the most com-
mon neuropathological hallmark present in both sporadic 
and familial ALS [4, 35]. TDP-43 is an RNA-binding protein 
(RBP) responsible for multiple RNA-processing functions 
including regulation of RNA stability, splicing, and trans-
lation [27, 37]. (2) A significant number of fALS causing 
mutations occur in genes encoding RBPs including TARDBP 
(TDP-43), FUS (TLS), TAF15, HNRNPA2B1, HNRNPA1 
and EWSR1 [42]. (3) The most common genetic cause of 
ALS is the recently discovered hexanucleotide repeat expan-
sion in the gene C9orf72 (C9ALS), where one of the main 
mechanisms may involve inhibition of RBPs by transcribed 
toxic RNA and patients exhibit widespread RNA processing 
alterations [38]. Together, these observations suggest that 
altered RBP localization and activity are conserved features 
of motor neuron disease in both fALS and sALS.
Unbiased profiling of expression and RNA processing 
patterns can reveal disease mechanisms, clinically relevant 
biomarkers, and converging pathways that underlie hetero-
geneous phenotypes of the diverse groups of ALS. While 
the lack of animal models for the sporadic form of the dis-
ease has shifted the focus of research to monogenic models, 
an alternative strategy is to interrogate molecular changes 
occurring in human patient tissues [14]. Prior studies have 
primarily used two approaches to study postmortem ALS 
tissues: homogenized bulk tissue and cell type specific-
enriched tissues. Homogenized tissues fail to capture the 
complex heterogeneity of the nervous system in which 
mainly one neuronal population undergoes degeneration. 
Meanwhile, cell-enriched profiling selectively examines 
neuronal RNA pools by dissection [15] or laser capture 
microdissection (LCM) [12, 13, 22, 39]. Simultaneous 
profiling of LCM-captured MNs and the immediately sur-
rounding anterior horn tissue have identified robust gene 
expression differences in the MN compartment that failed to 
be identified by analyses of the anterior horn, highlighting 
the lack of appropriate resolution in studies using homog-
enized bulk tissues [39]. A comprehensive systems-based 
gene-expression analysis of C9orf72 fALS [12] and a study 
correlating gene-expression with p62-pathology, a second 
neuropathological marker for sALS beside TDP-43, has 
been assessed to further explore disease mechanisms [13]. 
To date, genome-wide gene expression studies of sALS have 
not successfully identified useful candidates that explain dis-
ease pathology and mechanisms.
Clinical observations suggest that neurodegeneration 
in ALS begins focally and progresses neuroanatomically 
over the course of disease. The site of onset and distribu-
tion of involvement between UMNs and LMNs are key 
determinants of phenotype [41] since MNs in anatomical 
regions distant from the site of onset, while in the path of 
degradation, often appear to be relatively unaffected or in 
early stages of degeneration at the time of death [40]. For 
example, impaired neuronal control of respiratory muscles 
often occurs early in the clinical course of ALS while other 
somatic motor functions remain intact [45], and conversely, 
patients kept alive by maintaining respiratory function on 
ventilators gradually progress to a locked-in state of total 
motor control loss [34]. Therefore, sALS is unique in that 
the degeneration of MNs innervating the respiratory mus-
cles is the critical determinant of survival, whereas other 
neurodegenerative diseases patients exhibit respiratory dis-
tress in more advanced stages of neurodegeneration. Thus, 
while neuropathology of most degenerative diseases typi-
cally progresses uniformly to end-stage neuropathology, in 
ALS degeneration is dispersed three-dimensionally [40] and 
staging of ALS neuropathology is currently based on the 
anatomical distribution of pTDP-43 inclusions, not chrono-
logical progression [7].
Consideration of the neuroanatomical progression of ALS 
can be exploited to carefully dissect and capture molecular 
signatures of susceptible but surviving neuronal populations 
[39]. Here we have isolated surviving MNs from the lumbar 
spinal region of sALS patients with rostral onset and caudal 
disease progression and relatively early respiratory failure 
by LCM and profiled gene expression by RNA-sequencing. 
We applied a stringent analytical approach to identify unique 
transcriptomic signatures predictive of sALS histopathol-
ogy. Comparison of transcriptomic and histopathologic data 
revealed that mRNA expression levels of the kinase CSNK1E 
were highly correlated to phospho-TDP43 (pTDP-43) 
pathology. Enhanced crosslinking and immunoprecipitation 
combined with high-throughput sequencing (eCLIP) [49] 
demonstrated that TDP-43 bound to the 3′ UTR of CSNK1E 
RNA, which was upregulated in sALS, and loss of TDP-43 
function in vitro led to altered CSNK1E mRNA levels. CK1E 
protein encoded by CSNK1E displays protein–protein inter-
action with TDP-43 and increased expression of CSNK1E 
resulted in an increase in TDP-43 phosphorylation. Thus, 
we exploited unique features of sALS neurodegeneration to 
elucidate interplay between gene expression changes, TDP-
43 and its phosphorylation directly in affected sALS patient 
tissue. These observations provide an alternative approach 
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to uncover mechanisms underlying sALS pathology, and 
identify CK1E as a possible therapeutic target modulating 
TDP-43 phosphorylation.
Methods
Tissue acquisition and pathological screening
All nervous systems were acquired by way of an Investiga-
tional Review Board and Health Insurance Portability and 
Accountability Act compliant process. The sALS nervous 
systems were from patients who had been followed during 
the clinical course of their illness and met El Escorial cri-
teria for definite ALS. Genetic variants that are known to 
cause ALS were excluded. MN burden (MNB) was scaled 
from − 2 (largely UMN involvement) to + 2 (largely LMN 
involvement), whereas 0 is an equal contribution of UMNs 
and LMNs. Nervous systems selected for profiling for sALS 
were from patients who had bulbar or arm onset of disease 
and caudally progressing disease and thus had abundant 
residual MNs in the lumbar region at the time of death. Con-
trol nervous systems were from patients from the hospital’s 
critical care unit when life support was withdrawn. Upon 
death, an on-call tissue acquisition team performed autop-
sies immediately. Tissue collections were completed within 
6 h, usually within 4 h, of death and the entire motor system 
was dissected and archived for downstream applications by 
creating two parallel tissue sets from alternating adjacent 
regions. For molecular studies, segments were embedded 
in cutting media, frozen on blocks of dry ice and stored at 
− 70 C. For structural studies, the adjacent segments were 
fixed in 70% neutral buffered formalin, embedded in paraf-
fin (formalin-fixed paraffin-embedded or FFPE) and stored 
at room temperature. Because of received spinal radiation 
therapy, control 42 was withdrawn form study after initial 
expression profiling.
Laser capture microdissection (LCM) and RNA 
extraction
Laser capture microdissection was done according to the 
protocol described previously [39]. Briefly, 35–50 sections 
of frozen OCT-embedded human lumbar spinal cord were 
cut at a thickness of 9 µm in a − 18 C cryotome and placed 
onto uncharged glass slides. The sections were returned 
immediately to − 78 C after production, and maintained at 
that temperature for a minimum of 3 h. Staining with cresyl 
violet acetate was accomplished in a 10-step, timed, nucle-
ase-free immersion process. MNs were microdissected from 
each slide using a Pixcell IIe Laser Capture Microdissec-
tion (LCM) System (Arcturus Bioscience) and CapSureTM 
Macro LCM Caps (Applied Biosystems). Each LCM session 
had an upper time limit of 2.5 h. In addition to the MN 
enriched LCM material, the remaining anterior horn region 
was collected to create a second parallel pool. RNA isolation 
was carried out in each using an RNeasy Micro kit (Qiagen), 
which employs guanidinium isothiocyanate and 2-mercap-
toethanol extraction and column purification, including an 
on-column DNase I digestion step. Aliquots of each RNA 
pool were analyzed for quality and quantity on a Bioanalyzer 
RNA Pico chip (Agilent) and only those samples with RNA 
Integrity Numbers (RINs) > 5 or evidence of 28S peaks on 
the electropherogram tracings were advanced to the next 
step.
RNA‑seq library preparation and sequencing
Total RNA (10 ng) was amplified to cDNA using random 
priming with the  Ovation® RNA-Seq System (NuGEN). 
This procedure involved initial generation of double-
stranded cDNA followed by amplification through produc-
tion of single-stranded cDNA using the  SPIA® process. The 
single-stranded cDNA was then copied into double-stranded 
cDNA and quantified using the PicoGreen kit (Invitrogen) 
assayed with the FUSION system (Packard Biosciences), 
resulting in a total yield of 3–4 ug amplified cDNA’s. Stand-
ard concentration curves using bacteriophage lambda DNA 
were generated for each PicoGreen analysis, and the samples 
were diluted by tenfold serial dilutions. QC of the ampli-
fied cDNA was determined using a Bioanalyzer running an 
RNA 6000 Nano LabChip (Agilent). Double-stranded cDNA 
(1–2 μg) was fragmented to 150–200 bp sizes using Adap-
tive Focused Acoustics™ (Covaris, Inc., Woburn, MA), and 
QC of the fragmented cDNA was performed using a Bio-
analyzer DNA Chip 1000 (Agilent). Fragmented cDNA’s 
were concentrated using the QIAquick PCR Purification Kit 
(Qiagen) and 200 ng of the fragmented cDNA’s (determined 
following PicoGreen quantitation) were end-repaired, fol-
lowed by adaptor ligation onto the fragments and amplifica-
tion using the  Encore® NGS Library System I (NuGEN). 
Library QC was performed using a Bioanalyzer DNA Chip 
1000.
Gene‑expression analysis of RNA‑seq data using 
DESeq 2
Reads were aligned to UCSC genome browser human 
genome hg19 build using STAR alignment software with 
standard parameters published previously [24]. The aligned 
reads were assigned to the gencode annotation (release 17) 
and RPKMs were calculated to estimate gene expression. 
Genes with a sum of more than four counts across the sam-
ples were considered. Differentially expressed genes were 
determined by the DESeq 2 software [32] with a  log2 fold 
change (FC) > |1| and an adjusted P value < 0.05. GO-term 
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analysis was performed using the online functional annota-
tion tool DAVID [20] and categories with Benjamini–Hoch-
berg P values < 0.05 were reported. Hierarchical clustering, 
z-scores and correlations were computed using the seaborn 
package (version 0.7.1) in python (3.3). To extract genes 
with a high PC1-eigenvalue, the first 22 principal compo-
nents were calculated for each gene in the dataset using the 
R platform (version 3.3.1). To obtain a dataset with fewer 
confounding factors, 1000 genes with the highest PC1-eigen-
values were subtracted from the original dataset. Immune 
and wounding-related genes for testing enrichment/depletion 
of such were defined as genes that occur in the EMBL-EBI 
umbrella GO terms ‘immune system process’ (GO:0002376) 
and ‘response to wounding’ (GO:0009611). Hypergeomet-
ric test was used to calculate significance. Differentially 
expressed genes of the reduced dataset were determined 
as before. The iterative randomized dataset was generated 
by shuffling and picking 370 genes (RPKM sum across 
samples > 0) using the pandas program (version 0.18.1) in 
python. Spearman correlation coefficients were calculated 
for each random gene set for all samples and averaged across 
10,000 iterations and clustered as described before.
Fluidigm qPCR validation
High-throughput qPCR validation was carried out on Flui-
digm’s Biomark HD system, as described in manufacturer’s 
protocol. Specifically, cDNA (6.25 ng) was pre-amplified 
using 50 nM pooled primer mixture and TaqMan PreAmp 
Master Mix (Applied Biosystems) for 13 cycles. Unincor-
porated primers were removed with 8U of Exonuclease I 
(NEB) and the reaction products were diluted 10-fold in 
TE Buffer (TEKnova). The treated cDNA’s (280 pg) were 
combined with SsoFast EvaGreen Supermix with Low ROX 
(Bio-Rad) and loaded onto the 96.96 Dynamic Array inte-
grated fluidic circuit (Fluidigm). The overlap of Fluidigm 
results with RNA-seq was performed by comparing the fold-
changes found for the specific pairwise comparison. For a 
particular gene in a single pairwise comparison, if Fluidigm 
fold-changes was greater than a  log2(fold change) > |2| in the 
same direction as indicated by the RNA-seq, the gene was 
considered to be validated positive.
H&E and IHC staining and analysis of spinal cord 
sections
H&E was performed in the standard manner. For IHC, sec-
tions were stained with antibodies raised against CX3CR1 
(sc-20432, Santa Cruz Biotech, Inc.), phosphorylated TDP-
43 (CAC-TIP-PTD-P02, Cosmo Bio) and CSNK1E (A302-
135A, Bethyl Laboratories, Inc.).
CX3CR1-positive cells in the areas surrounding morpho-
logically intact (viable at the time of autopsy) MNs (100 µm 
radius) were counted for five MNs per patient and control. 
For each slide, we quantified the number of total morpho-
logically intact MNs (tMNs) as well as the number of phos-
phorylated TDP-43 (pTDP-43) positive MNs. Percentage 
of pTDP-43 positive MNs was calculated by normalizing 
pTDP-43 positive MNs to tMNs. The percent surviving MNs 
for each slide was calculated by normalizing sALS tMNs to 
control tMNs. Two users quantitatively analyzed three lum-
bar SC sections per sALS patient in a blind manner.
Molecular staging and correlation of gene 
expression with pTDP‑43
sALS patients were staged as ‘mild’ or ‘severe’, depending 
on their gene expression clustering. ‘mild’ and ‘severe’ has 
no correlation with disease severity or duration of disease. 
Additionally, patients were grouped into a ‘low’ and ‘high’ 
pTDP-43 group with the estimated percentages of neurons 
containing pTDP-43 accumulations. The ‘low’ and ‘high’ 
pTDP-43 was defined by the assumption that the highest 
rank in pTDP-43 status in the ‘mild’ group defines the cut-
off between ‘low’ and ‘high’ pTDP-43. The hypothesis was 
tested using Fisher’s exact test.
RPKMs were  log2 transformed, filtered  (log2RPKM > 1) 
and correlated with the respective percentage of pTDP-43 
in sALS patients using a Pearson correlation coefficient. A 
stringent value of r > |0.8| was considered as highly corre-
lating. The randomized correlation set was determined by 
permuting the estimated percentages five times across all 
samples.
TDP‑43 RNA targets in post‑mortem brain tissue
To identify TDP-43 RNA targets, eCLIP was performed and 
the datasets were processed as previously published [49]. 
Briefly, the frozen frontal cortex was homogenized in liq-
uid nitrogen and UV-cross linked in PBS. Afterwards, the 
tissue was frozen again and stored at − 80 °C for further 
processing. An equal amount of tissue from the five donors 
(ctrl, n = 2; sALS, n = 3) was lysed, sonicated and cleared. 
TDP-43 was immunoprecipitated on Dynabeads using an 
anti-TDP-43 antibody (Bethyl Laboratories Inc., A303-
223A). After transfer on nitrocellulose, a 70 kDa fragment 
(beginning from 40 kDa) was cut from the membrane of the 
IP and the respective size-matched input (SMinput) control. 
Sequencing libraries were sequenced with 50 bp paired-end 
sequencing at a depth of ~ 10 million reads for each library. 
For the analysis, reads were adapter trimmed and mapped 
with STAR (v2.4.0i) to the human genome (hg19). Custom 
scripts were used to remove PCR duplicated reads as previ-
ously described [49]. CLIPper was used to call peaks [31]. 
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Peak regions that passed a  log2 fold change (reads in IP/
reads in input) greater than 1 and a – log10 p value (deter-
mined from a Fisher’s exact test) greater than 2 were kept for 
downstream analyses. Kvector (https ://githu b.com/olgab ot/
kvect or) was used to count 6-mers in all peaks that passed 
filtering criteria (-log10 p value > 2,  log2 fold change > 2 over 
input). 6-mers were also counted from a random shuffled 
background list of peaks with the same genic distribution 
as foreground peaks. The frequency of occurrence for each 
6-mer was compared in the foreground and background 
using a Z test. 6-mers that are in the top 5 Z scores of any 
dataset were identified as the most highly enriched and are 
included on the plot in Fig. S7a (Online Resource 12). For 
the cross-comparison, significant peaks were assigned to 
genes using the gencode annotation. First, the transcripts of 
controls and sALS were overlapped within their respective 
group, generating a set of transcripts consistently bound in 
either controls or sALS. Subsequent identification of the 
overlap between the two groups resulted in a gene set sig-
nificantly bound by TDP-43 in all five samples. This set 
was considered highly conserved and used for further down-
stream applications for overlap between TDP-43 binding and 
pTDP-43 correlating genes. To estimate if the remaining 
genes, not bound consistently in all samples, are part of a 
biological effect or rather due to heterogeneity, the sets were 
sequentially overlapped with each sample (conserved in con-
trols with all sALS samples, and vice versa).
Validation and cross‑analysis with previously 
published datasets
For validation of TDP-43 eCLIP signal in CSNK1E in the 
human brain, TDP-43 ENCODE eCLIP-seq dataset (ENC-
SR584TCR) and a previously published TDP-43 CLIP-seq 
dataset in mouse brain [37].
IPSC culture
An overview of all lines is present in Table S4 (Online 
Resource 17). The CV-B iPSC-line has been described 
previously [18]. The study approval for Ctrl-1-SC11 was 
granted by the local ethics committee (No. 4485, FAU Erlan-
gen-Nuernberg, Germany). IPSC were cultured on Matrigel 
coated dishes and fed all 24 h with mTesR1 (Stemcell Tech-
nologies). Upon reaching ~ 80% confluency, iPSC were pas-
saged using Accutase in a 1:3–1:6 ratio. After passaging and 
thawing, mTesR1 was supplemented with 10 µM Y27632 
(ROCK-inhibitor, RI, Tocris).
MN differentiation
Human iPSC were differentiated according to using dual-
SMAD inhibition [9] which has been previously modified 
to generate MNs and characterized by our group [33]. IPSC 
were plated with 100% confluency on Matrigel-coated 
dishes. One day later, differentiation was induced by chang-
ing the media to DMEM/F12 + GLUTAMAX (Thermo 
Fisher Scientific) with 1% N-2 and 2% B-27 Supplement 
(Thermo Fisher Scientific), 100 µM Ascorbic acid (Sigma-
Aldrich) and 1% Pen/Step (media combination further 
referred as MN-base), supplemented with 1 µM Dorsomor-
phin (DO), 10 µM SB431541 (SB) and 4 µM CHIR99021 
(Tocris) daily until day six of differentiation. From day 
seven through day 15, the cells were fed with MN-base sup-
plemented with 1 µM DO, 10 µM SB, 5 µM RI, 200 nM 
Smoothened Agonist (SAG, EMD Biosciences) and 1.5 µM 
Retinoic Acid (RA, Sigma Aldrich). On day 15, the cells 
were split with the option to freeze the precursors in liquid 
nitrogen. For further differentiation, the cells were seeded at 
a density of 55,555 cells per  cm2 on Poly-d-Lysine (Sigma-
Aldrich) + Laminin (Thermo Fischer Scientific) coated 
plates in MN-base supplemented with 200 nM SAG, 1.5 µM 
RA, 5 µM RI, 2 ng/mL each of Ciliary Neurotrophic Fac-
tor (CNTF), Brain-Derived Neurotrophic Factor (BDNF), 
and Glial Cell-Derived Neurotrophic Factor (GDNF) (Pep-
rotech). For further differentiation into MN, cells were fed 
for 3 days from day 22 on with MN-base with 2 µM DAPT 
(Tocris), 5 µM RI, and 2 ng/ml BDNF, GDNF and CTNF. 
The final maturation step is induced on day 25 by withdrawal 
of DAPT. For this, the cells were washed with MN-base and 
further cultured in MN-base supplemented with 5 µM RI and 
2 ng/ml BDNF, GDNF and CTNF. The cells were harvested 
on day 30 for biochemical analyses. To induce TDP-43 phos-
phorylation, MNs were stressed with 100μM ethacrynic acid 
and 10μM FK506 (Tacrolimus) for 6 h.
Radiolabeling of RNA bound to protein
MNs were UV cross-linked and flash frozen. After plus or 
minus RNase treatment, an antibody specific for pTDP-43 
(CAC-TIP-PTD-M01, CosmoBio) or TDP-43 was used to 
pull down RNA bound to the respective proteins. Wash steps 
were performed according to the eCLIP-protocol. The RNA 
was labeled with 32P subsequently. Samples were run on a 
gel, transferred on a nitrocellulose membrane and developed 
on a film.
Lentivirus production and transduction
CSNK1E was cloned from a pENTR221 plasmid 
(HOC12375, GeneCopoeia) into the pLEX_307 plasmid 
(gift from David Root, Addgene plasmid # 41392) using 
gateway technology. Lentivirus was produced with a second-
generation virus prep using psPAX2 and pMD2.G plasmids. 
For knock-down experiments, previously published TAR-
DBP and scrambled (SCR) shRNAs were used [24]. The 
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cells were transfected in 293xT cells in DMEM + 20% FBS 
using PEI transfection reagent. The supernatant was col-
lected on day one and day two after transfection and pooled 
together. Virus was prepared according to the Lenti-X Con-
centrator kit (Clontech) and concentrated to a 100×. On day 
27 and day 28 the respective MN media was supplemented 
with 1% of the 100 × virus concentrate and iPSC-derived 
MN from three genetically different donors were trans-
duced. On day 37, the neurons were fixed in 4% PFA at RT 
for 5 min and rinsed in PBS three times. For knock down 
experiments motor neuron progenitors were infected on day 
16 of differentiation and harvested 4 days later. Knock down 
experiments were performed three independent times in the 
CV-B cell line.
qPCR
RNA from motor neuron progenitors was extracted using 
Trizol and reverse transcribed using SuperScript III (Invit-
rogen). Power Sybr Green PCR Master Mix (Applied Bio-
systems) was used to perform qPCR on a BioRad CFX 384 
system. 1 µM of the following primers were used: CSNK1E-
F GAA TTC CCG TTC TCC TGT GTCTA; CSNK1E-R AAA 
ACC AGG AAT GGA AGA TGGAG; CSNK1D-F CGT GCC 
AAG ACT AGC TCA GAAAA; CSNK1D-R CAG ACT CTA 
CTT TCT GGC CGTGA; GAPDH-F ACA GTC CAT GCC ATC 
ACT GCC; GAPDH-R GCC TGC TTC ACC ACC TTC TTG; 
HPRT-F CCT GGC GTC GTG ATT AGT G; HPRT-R TCC 
CAT CTC CTT CAT CAC ATC. The delta–delta-Ct method 
was used to estimate relative gene expression. GAPDH and 
HPRT served as controls.
Co‑Immunoprecipitation and western blot
For Co-Immunoprecipitation (Co-IP), the cells were lysed in 
500 µl RIPA buffer (50 mM Tris–HCl (pH 7.4), 1% NP-40, 
0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM 
EDTA, 20 mM NaF) supplemented with protease inhibitor 
(Roche), and lysed on ice for 15 min, followed by a soni-
cation and 20 min centrifugation at 18,000 g for 20 min 
at 4 °C. TDP-43 was immunoprecipitated on Dynabeads 
overnight with an anti-TDP-43 antibody (Bethyl Labora-
tories Inc., A303-223A). Beads were washed twice with 
high salt wash buffer (50 mM Tris–HCl (pH7.4), 1 M NaCl, 
1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5% sodium deoxy-
cholate), followed by two washes of wash buffer (20 mM 
Tris–HCl (pH7.4), 10 mM  MgCl2, 0.2% Tween-20). Beads 
were resuspended in 26 µl wash buffer, 10 µl 4xNuPAGE 
SDS buffer (Thermo Fisher Scientific) and 100 µM DTT 
up to a volume of 40 µl. Thirty microliter were added to a 
4–12% SDS Page gel (Thermo) for CSNK1E western blot, 
and 10 µl were applied for TDP-43 IP-validation. Western 
blot was performed using 4–12% BT running gels, (10 well, 
1.5 mm thickness, life technologies) and transferred on a 
PVDF membrane. NuPAGE running buffers (life technolo-
gies) were used. The membranes were blocked with 5% milk 
in TBS-T and incubated with the following primary anti-
bodies: TDP-43 (1:5000, Bethyl Laboratories Inc., A303-
223A), CSNK1E (1:2500, A302-135A, Bethyl Laboratories, 
Inc.). For detection, TrueBlot secondary anti-rabbit (1:1000, 
18-8816-33, Rockland Immunochemicals) was used.
Immunofluorescence staining of spinal cord 
sections and cultured cells
Tissue sections were cut from blocks of formalin-fixed par-
affin embedded tissue. 6 µm-thick tissue sections were de-
paraffinized through histology grade CitriSolv (two times for 
15 min each) and a graded alcohol series (100, 90 and 70% 
ethanol for 5 min each). After a 20 min permeabilization 
step in 1 × PBS and 0.2% Triton-X100, antigen retrieval was 
performed with a 1% Tris-based antigen unmasking solution 
(Vector Laboratories) in a pressure cooker at 120 °C for 
20 min. Sections were further blocked with 2% Fetal Bovine 
Serum (vol/vol, S11150, Atlanta Biologicals) and incubated 
with pTDP43 antibodies (1:1000; CAC-TIP-PTD-M01, Cos-
moBio), CSNK1E (1:500; A302-135A, Bethyl Laboratories, 
Inc.) and βIII-tubulin (1:1000; ab107216, Abcam) overnight 
at 4 °C. Afterwards, sections were washed three times in 
PBS 1X and blocked with 2% Normal Donkey Serum (Mil-
lipore S30-100 ml) before incubation with secondary anti-
bodies in PBS, 2% Normal Donkey Serum for 1 h at room 
temperature. For detection of primary antibodies, donkey 
anti-rabbit, anti-mouse Alexa-488, Cy3 conjugated antibod-
ies (Jackson ImmunoResearch) and goat anti-chicken Alexa 
633 conjugated antibody (A-21103, Invitrogen) were used 
at a 1:500 dilution. An incubation with DAPI (1 μg/ml) fol-
lowed of a PBS wash was performed. To reduce auto fluo-
rescence noise, quenching with 0.1% Sudan Black in 70% 
EtOH for 15 s was applied prior to coverslip mounting with 
ProLong Gold anti-fade mounting media (Invitrogen).
Imaging was performed on a Zeiss LSM 780 confocal 
microscope at 63x magnification under the same microscope 
conditions. Z-stacks of 0.5 µm size were taken.
For the staining of in vitro-derived MNs, the fixed cells 
were permeabilized in 0.3% Triton-X-100 and blocked with 
5% goat serum in PBS for 30 min, followed by an incuba-
tion of the primary antibodies pTDP43 antibodies (1:1000; 
CAC-TIP-PTD-M01, CosmoBio), CSNK1E (1:1000; A302-
135A, Bethyl Laboratories, Inc.) and βIII-tubulin (1:1000; 
ab107216, Abcam)) at 4 °C over night. After rinsing the 
cells twice in PBS, the secondary antibodies were incubated 
at a 1:500 dilution for 1 h at room temperature in the dark, 
subsequently stained with DAPI and rinsed five times in 
PBS.
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Images were taken with a Zeiss LSM 780 confocal 
microscope under the same conditions. Images were taken 
with z-stacks of 1 µm. The files were analyzed using 
ImageJ. Briefly, the cell and nucleus were surrounded 
manually and the pTDP-43 channel is subject to an inten-
sity thresholding. The binary image is now subject for 
analysis of the accumulations. An accumulation is called 
if a spot is bigger than 0.1 µm2. To obtain the number of 
cytoplasmic accumulations, the number of accumulations 
called in the nucleus is subtracted from the number of 
accumulations in the whole cells.
Data accession
The NCBI GEO accession number for the RNA-seq from 
post-mortem tissue reported in this paper is GSE76220. 
The TDP-43 eCLIP-seq dataset from frontal cortex is 
accessible through GSE103225.
Statistical analysis
GraphPad Prism 5.0 software was used to compute P values 
and linear regression analysis of CSNK1E. Pair-wise com-
parisons were performed using either t test or Mann–Whit-
ney-U-test and significance in contingency tables were deter-
mined by Fisher’s exact test. A difference was considered as 
significant if the P value was below 0.05.
Results
Laser capture microdissection results in specific 
enrichment for motor neuron signature
Laser-capture microdissection (LCM) of lumbar spinal 
cord sections from 13 sALS patients and 9 control patients 
(Table 1) was performed to obtain transcriptome-wide 
gene expression measurements in adult MNs. The sALS 
patients studied had rostral onset and caudal disease spread 
and relatively early respiratory failure. Thus, abundant 
Table 1  Clinical data of patient and controls and respective RNA integrity number (RIN)
MSF multi system failure, ARDS acute respiratory distress syndrome, ARF acute renal failure, CVA cerebrovascular accident
Patient No. Primary diagnosis Age Gender Site of onset Disease 
course 
(years)
Cause of death PMI (h) RIN
16 sALS 61 Male Arm 2.5 NA 3.5 6.1
21 sALS 84 Male Respiratory & hand 1.2 NA 2 6.8
27 sALS 74 Male Bulbar 3.25 NA 4 5.2
34 sALS 81 Female Bulbar 1 NA 3.5 4.3
48 sALS 67 Male Bulbar 1.75 NA 6 6.8
60 sALS 58 Female Bulbar 3 NA 3 5.6
62 sALS 52 Male Arm 1.67 NA 6 5.1
63 sALS 68 Male Arm 2.5 NA 5 6.4
79 sALS 55 Male Arm NA NA 5 6.1
82 sALS 54 Male Bulbar 2.5 NA 8 5.4
84 sALS 56 Female Bulbar 2 NA 4 5.9
85 sALS 77 Female Trunk 2.3 NA NA 6
89 sALS 36 Male Bulbar 3 NA 5 5.9
Mean 63 9 M, 4F 2.2 4.6 5.8
10 Control 78 Male NA NA Sepsis/pulmonary hypertension 2.5 5.0
39 Control 77 Male NA NA Aortic dissection/MSF 2 6.2
42 Control 61 Male NA NA Brain tumor 6 5.8
44 Control 80 Female NA NA Liver failure 5 5.8
65 Control 82 Male NA NA NA 4 5.4
67 Control 77 Male NA NA NA 4 5.4
76 Control 68 Male NA NA Sepsis, ARDS, ARF 4 6.0
78 Control 58 Female NA NA Vasculitis, cerebral hemorrhage 3 5.4
88 Control 78 Female NA NA CVA, MSF 3.8 5.8
Mean 73 6 M, 3F 3.8 5.6
412 Acta Neuropathologica (2018) 136:405–423
1 3
residual MNs in the lumbar region were often present at 
the time of death (Fig. 1a). Total RNA was extracted and 
amplified using random priming, converted into cDNA, 
linearly amplified, fragmented and prepared as a sequenc-
ing library (Fig. 1a). The quality and quantity of products 
was evaluated at each step using capillary electrophore-
sis and reporting RNA integrity numbers (RIN; Table 1). 
High-quality libraries from samples with RIN values > 5 
and/or had 28 and 18 s peaks in electropherograms were 
submitted for high-throughput Illumina sequencing. 
The 22 RNA-seq libraries were sequenced to an average 
depth of ~ 28 million reads per sample [Table S1 (Online 
Resource 1)].
To evaluate if the capture and microdissection success-
fully enriched for MNs, we included RNA-seq data from 
MNs independently differentiated from induced pluripotent 
stem cells (iPSCs) as comparison for an early MN signa-
ture (Fig. 1b), as well as human embryonic kidney cells 
(HEK293T) as a non-neuronal comparison. We found that 
essentially all genes in our neuronal panel were enriched 
in the LCM-isolated MN samples over the HEK293T cells 
and exhibit a similar pattern as the iPSC-derived MNs. An 
astrocyte marker SB100 and microglial markers PTPRC and 
CX3CR1 were also enriched in our MN pool (Fig. 1b). We 
concluded that the LCM followed by RNA-seq approach was 
successful in obtaining a MN-enriched population of cells 
from sALS and control patients, recognizing that other cell 
types such as astrocyte and microglia closely connected with 
MNs were also unavoidably present.
RNA‑seq data analysis of sALS MNs identifies unique 
gene‑expression signature
We first performed principal component analysis (PCA) on 
the gene expression data to evaluate if sALS and controls can 
be distinguished. Intriguingly, most sALS samples and con-
trols tend to cluster separately along the PC1 axis, explaining 
49% of the variance in the data (Fig. 2a). To identify differ-
ential expression in LCM-enriched MN samples that distin-
guish sALS from control individuals, we used DESeq 2 [32], 
a routinely used software to establish statistically significant 
gene expression changes. DESeq 2 revealed 972 significantly 
upregulated genes in the sALS samples relative to controls, 
with 67 genes with lower expression levels  (Log2FC > 1 and 
an adj. P value < 0.05, Data S1a (Online Resource 2). These 
1039 genes clearly segregated the control and disease groups 
(Fig. 2b). Gene ontology (GO)- analysis of the DESeq 2 
dataset showed a strong enrichment for genes involved in 
the immune response and wound healing [Fig. 2c, left side 
and Table S2 (Online Resource 3)]. To validate the sequenc-
ing approach, we additionally used targeted gene-specific 
high-throughput qRT-PCR analysis on the Fluidigm Bio-
mark platform. Most differentially expressed genes were also 
found to be dysregulated by qPCR (78.5%) [Fig. S1a (Online 
Fig. 1  Laser capture microdissection (LCM) isolates viable lumbar 
MNs from respiratory onset sALS patients. a Study paradigm: dis-
ease progresses caudally in sALS patients with respiratory onset. At 
the time of death, spinal MNs proximal to the site of onset (cervi-
cal) have succumbed, whereas distal MNs (lumbar) remain. These 
MNs are captured via LCM and subjected to RNA-seq. b Heatmap 
of RNA-seq derived gene expression signature of LCM MNs for con-
trols and sALS samples showing enrichment of neuronal and glial 
markers. Two independent iPSC-derived MN lines and HEK293T 
(non neuronal) were used as controls. Color bar indicates  Log2 fold 
change over HEK239T non-neuronal cells
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Resource 4)]. Furthermore, the qPCR expression values of 
28 tested genes show a tendency to cluster sALS separate 
from controls [Fig. S1b (Online Resource 4)].
To determine whether this immune signature is intrinsic 
to neurons or rather a signal from surrounding immune cells, 
we performed H&E staining of lumbar spinal cord sections 
from these patients. We detected siderosis [Fig. S2a (Online 
Resource 5)] and infiltrating potential immune cells around 
blood vessels [Fig. S2b (Online Resource 5)] to varying 
degrees in sALS but not in controls. Immunohistochemis-
try for the microglial marker CX3CR1 (Fig. 2d) showed an 
enrichment of microglia within a 100 µm radius around MNs 
in sALS (Fig. 2e). In agreement with previous observations 
[13] and not surprisingly, we observe that there is a substan-
tial presence of the immune cell RNA signature in LCM MN 
samples in sALS.
Differential gene expression separates sALS 
patients according to their pTDP‑43 status
Immune activation and wounding-related transcripts were 
highly differentially expressed in the dataset and most likely 
mask certain interesting gene expression changes coming 
from the MN itself. To reduce this signature in an unbi-
ased fashion, we took a closer look at the top 1000 genes 
contributing to PC1 that accounted for the highest varia-
tion and segregated control and sALS samples [Fig. 2a and 
Data S1b (Online Resource 2)]. These 1000 transcripts show 
highly enriched immune GO terms (Fig. 2c, right side) and 
are significantly enriched in immune and wounding-related 
transcripts (16.6% of the top 1000 genes, fivefold more than 
random; P value = 5.11*10−70). Conversely, when we sub-
tract these 1000 genes from the original dataset, the reduced 
gene set (whole transcriptome minus 1000  PC1high genes) is 
significantly depleted in immune and wounding transcripts 
(P value = 2.344*10−68,; now containing 14% less immune 
and wounding related genes). We reanalyzed the reduced 
RNA-seq data (minus top 1000  PC1high genes) with DESeq 2 
and observed 370 differentially expressed (DE) genes (330 
upregulated and 40 downregulated,  Log2FC > 1 and an adj. 
P value < 0.05, Data S1c [Online Resource 2)]. Encourag-
ingly, this reduced gene set still separated the sALS sam-
ples from the controls (Fig. 2f). Intriguingly, we observed 
six new biological functions (in the top 10 categories) that 
were not observed in the full dataset or randomly chosen 
gene sets [Fig. 2g and Table S3 (Online Resource 6)] includ-
ing ‘aging’ (FDR adjusted P value = 0.0138) and ‘positive 
regulation of gene-specific transcription’ (FDR adjusted P 
value = 0.0137). Our results indicate that an ALS-specific 
gene signature independent of immune-related signals can 
be identified in MNs by LCM.
With these 370 DE genes, a Spearman correlation analy-
sis distinguished the sALS samples into two groups (Fig. 3a, 
left panel) with patient sample numbers 21, 79 and 63 group-
ing closer with controls rather than the other sALS samples. 
Randomly chosen sets of (370) genes did not show cluster-
ing of the sALS cases across 10,000 iterations (Fig. 3b, right 
panel). The gene expression profiles did not cluster differ-
ently according to RIN values (RNA quality), post-mortem 
interval, age, and an obvious involvement of UMN or LMN 
to the clinical phenotype (Fig. 3a). A clustering similar to the 
PC-1 adjusted dataset was observed when the genes within 
the three top gene ontologies (‘defense response’, ‘immune 
response’ and ‘response to wounding’) were subtracted from 
the original dataset [Fig S3 (Online Resource 7)].
We next stained sALS patient lumbar spinal cord sec-
tions for phosphorylated TDP-43 (pTDP-43), a hallmark of 
ALS. We examined the control cohort and as expected there 
was no immunoreactivity against pTDP-43 [Fig S4 (Online 
Resource 8)]. Expectedly, ALS MNs showed pTDP-43. We 
ranked the patient cohort in increasing order of pTDP-43 
positive MNs [Fig. 3b, c and Fig. S5a (Online Resource 9)]. 
We observed that samples with a ‘mild’ RNA signature also 
had lower pTDP-43 levels, and therefore, Patients 21, 79 and 
63 (‘mild’ RNA signature) are distinct from samples with 
high pTDP-43 levels [P value = 0.014 by Fisher’s exact test; 
Figs. 3c and S5b (Online Resource 9)]. Contrarily, samples 
with ‘severe’ gene expression changes had higher pTDP-43 
pathology. Our results suggest that the 370 gene signature is 
associated with pTDP-43 pathology in sALS.
CSNK1E expression is linked to TDP‑43 and its 
phosphorylation
To identify individual genes whose mRNA levels are cor-
related most with phosphorylated TDP-43 status in the indi-
vidual sALS patient samples, we calculated genome-wide 
Pearson correlation coefficients between the neuropatho-
logical pTDP-43 status [Data S2a (Online Resource 10)] 
and  log2RPKM of transcripts [Data S2b (Online Resource 
10)] in the patient dataset. We found that the distribution 
of correlation coefficients resulted in a positively skewed 
(skewed towards right) distribution. Out of all transcripts 
detected in the dataset (before subtraction of confounding 
immune genes), 291 genes were highly correlated (r > 0.8) 
with pTDP-43 pathology, while only 10 genes showed a 
strong negative correlation in patients [r < − 0.8, Fig. 4a 
and Data S2c (Online Resource 10)]. A randomly chosen 
set of genes illustrated a lack of correlation with pTDP-43 
pathology (Fig. 4a, grey curve). In contrast, when corre-
lated with morphologically assessed MN death [Figs. 3c and 
S5a (Online Resource 9)], we identified only 11 genes that 
passed our threshold [r > |0.8|, Fig. S6a (Online Resource 
11) and Data S2d (Online Resource 10)]. Interestingly, when 
these pTDP-43-burden correlated genes are compared to a 
published set of genes correlating with p62-inclusions as a 
414 Acta Neuropathologica (2018) 136:405–423
1 3
Fig. 2  Differential gene expression analysis in sALS reveals immune 
signature. a PCA plot representing genome-wide variance of control 
(blue) and sALS (red) LCM MN sample RNA-seq data along the first 
two PCs. b Unsupervised hierarchical clustering heatmap by correla-
tion distance of differentially expressed genes determined by DEseq. 
Color scale represents z-scores. c Three most significant biological 
function (green), cellular compartment (red) and molecular function 
(yellow) GO-terms (DAVID) enriched within significantly dysregulated 
genes (left), and 1000 genes with highest PC1-eigenvalues (right). d 
Representative immunohistochemistry (IHC) of a control and an sALS 
patient exhibiting CX3CR1-positive microglia (arrow) within a 100 µm 
radius (circle) of a MN. e Quantification of number of CX3CR1-pos-
itive microglia within 100  µm radius of MNs, (N sALS = 10, N con-
trol = 9). Graph represents median and interquartile range, Significance 
was calculated with Mann–Whitney-U-test (P value = 0.0204). f Unsu-
pervised correlation-distance based hierarchical clustering heatmap 
illustrating 370 differentially expressed genes (post filtering out PC1). 
Color scale represents z-scores. g Highly significant GO-terms of three 
GO categories that were not previously reported. Green = biological 
function, red = cellular compartment, yellow = molecular function
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different neuropathological measure of ALS [13], we only 
observed an overlap of two genes, raising the possibility of 
different mechanisms leading to the histopathological hall-
marks [Fig S6b (Online Resource 11)].
Next, we asked which of the transcripts that were highly 
correlated with pTDP-43 burden are also directly bound by 
the RBP TDP-43. We used enhanced UV cross-linking and 
immunoprecipitation (eCLIP) in the frontal cortex of two 
healthy controls and three sALS patients to profile the tran-
scriptome-wide RNA targets bound specific RBPs. eCLIP 
requires a high cell count, therefore motor cortices which 
have a higher density of surviving neurons in ALS cases 
were chosen over spinal cord. The technique features a size-
matched input control, enabling the ranked identification of 
RNA binding sites and RNA substrates above background. 
Motif analysis of RNA binding sites of TDP-43 confirmed 
the known GU-rich TDP-43 binding motif in all samples 
[Fig. S7a (Online Resource 12)]. We found 351 genes 
 (log2FC > 1, P value < 0.01) that show conserved TDP-43 
binding in both control and sALS groups [Fig. 4b, Venn 
diagram and Data S2e (Online Resource 10)]. To estimate if 
there is any overt tissue-wide loss of TDP-43 RNA binding 
activity in sALS, we estimated the transcripts bound only 
by controls [Fig. 4b, blue part of Venn diagram and Data 
S2f and S2g (Online Resource 10)] or sALS [Fig. 4b, red 
part of Venn diagram and Data S1h, S2i and S2j (Online 
Resource 10)] that represent a true loss of TDP-43 binding 
(and not biological heterogeneity) by analyzing each biologi-
cal replicate in the control group vs. each biological replicate 
in the sALS group (pair-wise analysis). Interestingly, only 
12 transcripts that were uniquely bound by TDP-43 in con-
trols showed a loss of binding in sALS samples suggesting 
that analysis of specific cellular populations and not whole 
brain regions is more likely to uncover any loss of the RNA-
binding capability of TDP-43 in sALS (Fig. 4b, pie charts) 
given the tissue heterogeneity of the frontal cortex.
By comparing the list of genes whose mRNA levels cor-
related with pTDP-43 burden and genes whose mRNA is 
bound by TDP-43 in the human brain (Fig. 4c) we identi-
fied several interesting candidates, such as the cytoskeleton 
component ACTN1, the putative splicing factor LUC7L and 
neurodevelopment and regeneration linked gene NAV1. 
Intriguingly, the top candidate was CSNK1E, a kinase that 
is implicated in TDP-43 phosphorylation [11, 23]. Indeed, 
regression analysis of pTDP-43 status in the respective 
patient lumbar spinal cord alone explained more than 93% 
of the variance in CSNK1E expression levels in sALS 
(Fig. 4d). Interestingly, CSNK1E did not fulfill our  log2 > 1.0 
fold change stringency criteria of in the standard DESeq 2 
analysis in the reduced RNA dataset  [log2FC = 0.9987, adj. P 
value = 0.0109, Data S1c (Online Resource 2)], emphasizing 
variation in human samples and importance of alternative 
approaches to average differential expression analyses to 
capture differences influenced by criteria other than a sim-
ple disease status.
TDP‑43 directly interacts with the 3′ UTR of CSNK1E 
mRNA in human brain and regulates its expression
To identify the region of the mRNA where TDP-43 binds, 
we evaluated our frontal cortex eCLIP datasets. We found 
that TDP-43 directly interacts with the 3′ untranslated region 
(3′ UTR) of CSNK1E in all five brain samples [Fig. 4e and 
Fig. S7b (Online Resource 12)]. A very strong binding in 
the 3′ UTR of CSNK1E is also observed in ENCODE (K562 
cell line) eCLIP datasets [49] [Fig. S7b (Online Resource 
12)] and in a previously published mouse brain dataset [37] 
[Fig. S7c (Online Resource 12)]. To further assess the pos-
sibility of RNA-binding capabilities of phospho-TDP-43, 
we artificially induced TDP-43 phosphorylation in iPSC-
derived MNs using a previously published combination of 
ethacrynic acid and tacrolimus [Fig. S8 (Online Resource 
13)] [28]. After UV-cross-linking, RNase digestion, and 
radiolabeling RNA with P-32 we were only able to pull 
down RNA in treated (induction of TDP-43 phosphoryla-
tion) but not non-treated samples using a pTDP-43 specific 
antibody, suggesting that the phosphorylated TDP-43 indeed 
binds RNA (Fig. 4f). Combined, our findings are consist-
ent with previous eCLIP data in revealing that TDP-43 
binds to the 3′UTR of CSNK1E and suggest a functional 
role of TDP-43, and potentially even pTDP-43 in regulating 
CSNK1E mRNA levels.
To elucidate if TDP-43 regulates CSNK1E mRNA levels, 
we performed TDP-43 knock-down in motor neuron progen-
itors using an shRNA. CSNK1E mRNA levels were reduced 
by 40% (P value = 0.0271; Fig. 5a), and CK1E protein lev-
els were similarly reduced (Fig. 5c) by 40% with TDP-43 
knock down. Interestingly, the mRNA levels of the CSNK1E 
homologue CSNK1D remained unchanged (Fig. 5b).
CK1E promotes TDP‑43 phosphorylation in human 
motor neurons
The Drosophila CK1E homologue known as doubletime is 
known to phosphorylate mutant TDP-43 [11]. We therefore 
tested if CK1E-positive MNs show pTDP-43 aggregation. 
Immunofluorescence of lumbar spinal cord sections indi-
cated that pTDP-43 positive MNs from sALS patients also 
showed CK1E staining (Fig. 6a), but no co-localization 
between CK1E and pTDP-43 [Figs. 6a, S9 (Online Resource 
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Fig. 3  Unsupervised clustering stages sALS patients in two groups 
based of pTDP-43 status. a Correlation heatmap clustering sALS 
(red) and control (black) LCM MN samples according to 370 differ-
entially expressed genes (left) or 10,000 × 370 random genes (right). 
Color scale represents correlation coefficients. Magenta arrowheads 
mark samples in the ‘mild’ gene expression group. Age, postmortem 
interval (PMI) and RNA integrity number (RIN) for individuals are 
represented in purple color scales. Motor neuron burden (MNB) of 
sALS patients indicates primarily upper MN (UMN) involvement 
(-2) in blue scales, lower MN (LMN) burden (+2) in red scales and 
equal contribution (0) of both MNs in white. b Representative IHC 
of pTDP-43 in sALS patients. Arrow marks morphologically nor-
mal MNs, dashed arrow marks morphologically degenerated MNs, 
arrowhead indicates pTDP-43 within MNs. c Quantification of TDP-
43-positive and MN degeneration in each patient (3 lumbar sec-
tions per sALS patient). Samples were ranked by their percentage 
of pTDP-43-positive MNs. Green arrow indicates ‘low’ p TDP-43 
group, while yellow marks the ‘high’ group. Magenta arrowheads 
indicate sALS samples clustering in ‘mild’ gene expression group
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Fig. 4  Neuropathology vs. gene expression correlations and TDP-
43 eCLIP reveal potential candidate genes. a Histogram of Pearson 
correlation coefficients  (log2 RPKM gene expression vs. pTDP-43 
metric) for each patient sample (green) or randomized values (grey). 
Analysis performed with all detected transcripts before subtraction of 
immune genes. b TDP-43 eCLIP-seq of motor cortex from controls 
(n = 2) and sALS patients (n = 3). Venn diagram shows overlapping 
genes between control (n = 2) and sALS (n = 3) identified by TDP-43 
eCLIP. Blue shows genes identified in both control samples (305), 
red shows genes identified in all sALS samples (62), magenta shows 
genes identified in all samples (351). Of the 305 genes conserved 
between both control samples, 293 were identified in at least one 
sALS sample (left pie chart). Of the 62 genes conserved between all 
sALS samples, 61 were identified in at least one control sample (right 
pie chart). c Pie chart showing genes highly correlated with TDP-43 
pathology (r > |0.8|, 301 genes) with 16 genes that are also bound 
by TDP-43. CSNK1E shows the highest correlation (r = 0.96) and is 
bound by TDP-43. d Scatter plot illustrating regression of CSNK1E 
 log2 RPKM vs. observed pTDP-43 status in respective sALS 
patients with fitted line and R2 value. e UCSC genome browser track 
shows binding of TDP-43 in the 3′ UTR of CSNK1E in the TDP-43 
CLIP but not in the inputs (no IP control). f Radiolabeling of RNA 
pulled-down with pTDP-43- (left) and TDP-43-specific antibody in 
unstressed and stressed MNs
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14)], differences in cellular localization or cell type specific-
ity in the whole spinal cord were observed [Fig. S10 (Online 
Resource 15)]. Next, we performed immunoprecipitation 
with an antibody against TDP-43, followed by western blot 
for CK1E to determine whether TDP-43 protein directly 
associated with CK1E in MNs differentiated from iPSC lines 
from three healthy individuals and one fALS patient with 
a TDP-43 N352S mutation. Indeed, we found co-immuno-
precipitation of CK1E in all four samples (Fig. 6b). Finally, 
to determine if CK1E upregulation increases TDP-43 phos-
phorylation and aggregation, we generated three separate 
iPSC-derived MN lines (iPSC-MN) from healthy donors 
stably expressing CSNK1E via lentiviral transduction (Fig. 
S11 (Online Resource 16)]. Remarkably, CK1E overex-
pression resulted in significantly more TDP-43 cytoplasmic 
accumulations compared to mock transfected MNs in each 
cell line (Fig. 6c, d). Therefore, our results demonstrate that 
CK1E interacts with and promotes TDP-43 phosphorylation 
in human MNs.
Discussion
Neuropathology in neurodegenerative disease is tradition-
ally considered to be a descriptive observation in end-
stages of the neurodegenerative processes. We exploited 
the unique anatomical progression of neurodegeneration in 
ALS patients to capture spared but at-risk MNs in the spinal 
cord and identify gene-expression signatures of sALS. Our 
approach utilized the following three criteria: (1) Tissues 
were collected specifically anticipating genomic studies 
using short post-mortem intervals and embedding tissues 
for cyrosectioning. (2) Patients had rostral symptom onset 
and caudal disease spread leaving residual spinal cord MN 
populations destined for degeneration in the lumbar region. 
3) Optimizing detection of neuronal RNA by laser capturing 
residual MNs to generate the RNA pools. Indeed, results 
showed that the pools were highly enriched for mature 
neuronal markers and we identified several differentially 
expressed genes.
Robust RNA‑seq data analysis detects Immune 
system involvement in sporadic ALS
We found more than 1000 differentially expressed genes 
using DEseq 2 and validated candidate genes using high-
throughput qPCR, achieving a concordance rate of 78.5%. 
Not surprisingly, a strong activation of the immune 
system including microglia was identified which was 
confirmed histologically. The microglial marker gene 
CX3CR1 was highly upregulated. CX3CR1 protein is 
the juxtacrine receptor for fractalkine localized on the 
plasma membrane of neurons and is believed to have 
a disease-modifying role in humans [30] and a protec-
tive role in the SOD1 G93A ALS mouse model [26]. We 
found significant upregulation of markers of adaptive 
immune cells such as CD4, CD22 and CXCR4 [Data S1a 
(Online Resource 2)], suggesting infiltration of periph-
eral immune cells such as T-lymphocytes. T-lymphocytes 
appear to play a protective role in SOD1 G93A mouse 
models [6, 10]. Additionally, a strong enrichment of com-
plement system genes was detected among the upregu-
lated dataset, including C1QB, C1QC and C3 [Data S1a 
(Online Resource 2)]. Complement system involvement 
is implicated in neuromuscular junctions [5] and spinal 
cords of ALS patients [46] before. Interestingly, our data 
indicates an increase in expression of the F3 tissue fac-
tor, the major initiating protease in the blood coagulation 
cascade. Vascular changes and blood-CNS barrier impair-
ment causing microhemorrhages have been reported in 
SOD1 ALS previously [16, 17, 43], making this an inter-
esting area for further analysis in the sporadic form of the 
disease. The presence of components of immune system 
in the ALS CNS is previously documented [3, 25, 48]. 
Fig. 5  TDP-43 regulates 
CSNK1E mRNA levels. a 
CSNK1E RNA levels deter-
mined by qPCR. Graph repre-
sents mean +SEM, significance 
was calculated with t test (P 
value = 0.0271). b CSNK1D 
RNA levels determined by 
qPCR. Graph represents 
mean +SEM, significance 
was calculated with t test (P 
value = 0.4538). c Repre-
sentative western blot showing 
reduced CK1E protein levels in 
TDP-43 knock down conditions
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Identification of immune cells and their receptors that 
interact with neuronal ligands may help in therapeutic 
development of neurodegenerative conditions similar to 
cancer immunotherapy. Our study provides an important 
resource of gene-expression signatures of immune cells 
that may physically interact with MNs.
It is noteworthy that expression level of the ALS-asso-
ciated frontotemporal-lobar degeneration (FTD) causative 
Fig. 6  TDP-43 is a substrate of CK1E. a Immunohistochemistry for 
CK1E and pTDP-43 in lumbar spinal cord sections show co-occur-
rence of these signals in the same cell. β-III tubulin marks neurons. 
Scale bar 20 µm. b Immunoprecipitation (IP) of TDP-43 from three 
control and one fALS patient (TARDBP mutation) iPSC-derived MNs 
shows CSNK1E co-IP with TDP-43 but not IgG. c Immunofluores-
cence (IF) for pTDP-43 after overexpression (OE) of either CSNK1E 
or mock (control) in three different iPSC-derived MN lines shows 
increased pTDP-43 aggregates in CSNK1E OE. Scale bar 10 µm. d 
Quantification of pTDP-43 signal from CSNK1E or mock OE iPSC-
MN lines described in c. Data represented as mean ± SEM. Mann–
Whitney-U test was used to determine significance
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gene GRN was upregulated before and after filtering data-
sets. Increased immunoreactivity of progranulin (PGRN), 
the GRN gene product, is observed in MNs of sALS patients 
[21]. Since PGRN is also extensively expressed in micro-
glia and upregulated in sALS patients [36], our observa-
tion of GRN mRNA levels could be a result of increased 
number of microglia surrounding MNs. Another possible 
reason for increased GRN levels could be altered regulation 
of its mRNA by TDP-43 [37]. Further studies are needed to 
elucidate the mechanism by which TDP-43 mediates GRN 
mRNA stabilization. However, this is consistent with the 
previous observation of increased GRN mRNA levels in 
TDP-43 knockdown mouse striatum [37].
These results also invoke the possibility of non-cell 
autonomous neurotoxicity such that activated microglia or 
other immune cells directly cause neurodegeneration but 
such mechanisms need to be further tested. Presence or 
absence of a cell type in a sample heavily affects differen-
tial gene expression profile. Thus, our findings highlight the 
ability of LCM followed by RNA-seq to enrich, detect and 
predict pathological cell types in the microenvironment of 
the targeted cell in an unbiased manner.
Disease characterization based on gene expression 
signature
Neurodegenerative disorders lack gene expression-based 
molecular characterizations especially of the neurons that 
are primarily affected in the disease and indeed most neu-
rodegenerative disease are far advanced by the time nerv-
ous systems are acquired. Despite these issues, we are able 
to do this in ALS due to the unique anatomical progres-
sion, death by respiratory failure, and ready identifications 
of MNs. Using a set of 370 differentially expressed genes 
[Data S1d (Online Resource 2)] in a dataset adjusted for con-
founders as described above, we characterized sALS based 
on an individual gene expression signature. After filtering 
immune-related genes, lumbar MNs from rostral onset sALS 
patients fell into two groups based on individual patient gene 
expression profiles, and importantly, the group correlating 
better with control subjects was found to have a significantly 
lower pTDP-43 burden, consistent with the hypothesis that 
these MNs were in relatively early stages of degeneration.
Profiling MNs from human spinal cord in this manner is a 
direct approach to unraveling the complexity of human dis-
ease, but clearly drawbacks are that the samples are geneti-
cally more variable than animal models and iPSC-derived 
neuronal cultures. Therefore, we noted two exceptions: con-
trol nervous system (#44) clustered closely with the ‘mild’ 
gene expression disease group, and one sALS patient (#84) 
that showed low pTDP-43 burden was classified as ‘severe’. 
Since aging was a significant GO term in our dataset, and 
control 44 is 80 years old (second oldest control individual 
in our cohort, Table 1), the clustering towards mild sALS 
might be due to an “aging” signature. Although sALS 84 did 
not cluster in the mild sALS group, it had higher correlation 
coefficients compared with the control samples than most 
of the other patients in the severe group. Clearly, greater 
sample numbers, stratification by UMN and LMN clinical 
disease burdens, better age-matched controls, and deeper 
sequencing in the future will explain such discrepancies that 
could be due to either false positives, aging, or genetic modi-
fiers. A future independent validation of this gene set in a 
second patient cohort will solidify the validity of our classi-
fier. More stringent criteria and reproducible measurements 
that define the two sALS classes (mild and severe gene 
expression) are required to establish precise high-throughput 
sequencing based molecular diagnostic marker panels.
Transcriptome–phenotype correlations and TDP‑43 
eCLIP‑seq reveal potential candidate genes
We aimed to identify candidates that were altered in sALS 
with increasing pTDP-43 burden using our RNA-seq and 
TDP-43 eCLIP-seq dataset. Using a similar approach, a 
gene expression—p62 neuropathology correlation in ALS 
was recently reported [13]. When we compared the datasets 
between our (pTDP43 vs. gene-expression) and the afore-
mentioned report (p62 vs. gene-expression), there was an 
overlap of only two transcripts. This observation may be 
explained by the fact that in contrast to p62, TDP-43 is an 
RBP, directly contributing to RNA expression changes in 
ALS. In addition, there were differences in the spinal cord 
region that was analyzed. While the current study focuses 
largely on the lumbar spinal cord in sALS patients who had 
rostral onset and caudal disease spread, the Cooper-Knock 
et al. report evaluated cervical spinal cords of lumbar-onset 
patients with rostral spread. Additionally, Cooper-Knock 
et al. utilized an equal number of C9orf72 and sporadic ALS 
patients in their study and a recent publication suggests dif-
ferential transcriptome expression in the frontal cortex of 
C9orf72 ALS patients in comparison to sALS patients [38].
Interplay between CSNK1E mRNA levels and TDP‑43 
phosphorylation
Using our pTDP-43 correlation analysis combined with 
TDP-43 eCLIP-seq, we identified interesting candidates 
such LUC7L, NAV1 and ACTN1. Our top candidate using 
this approach was casein kinase 1 epsilon (CSNK1E). 
RNA expression levels of CSNK1E exhibited the highest 
correlation with pTDP-43 status in sALS nervous systems 
(R2 = 0.93) and we also showed for the first time that TDP-43 
binds the 3′ UTR of CSNK1E mRNA by eCLIP-seq of TDP-
43 in frontal cortex. Additionally, we showed that TDP-43 
loss of function results in reduced CSNK1E levels. It was 
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surprising at first that our patient dataset revealed upregula-
tion of CSNK1E mRNA in sALS whereas TDP-43 knock-
down showed a decrease in the CSNK1E mRNA levels. 
However, it appeared plausible considering a recent study 
of TDP-43 knock-down in mice and an ALS mouse model 
expressing ΔNLS-TDP-43 (cytoplasmic overexpression and 
localization combined with nuclear loss of function) also 
showed altered gene expression in opposite directions [2]. 
Combined with our finding that pTDP-43 itself binds RNA, 
this supports toxic effects of cytoplasmic, pathological and 
phosphorylated TDP-43 on target RNAs in sALS separate 
from nuclear loss of function. Therefore, it is likely that 
disease models that increase cytoplasmic localization and 
aggregation combined with nuclear loss of TDP-43 function 
will better represent ALS [50].
It is still a matter of debate whether phosphorylated and 
aggregated TDP-43 has protective functions in ALS. The 
casein kinase family is known to phosphorylate TDP-43 
in vitro [19] and several casein kinase 1 subfamily depend-
ent TDP-43 phosphorylation sites have been elucidated [23]. 
Furthermore, phenotypes and cellular alterations of TDP-43 
in GRN mutation linked FTD patient blood derived lympho-
blastoid cells can be reversed by two blood–brain barrier 
permeable CK1D/E inhibitors [1, 44]. Additionally, the fly 
homologue of CK1E is known to phosphorylate mutant 
TDP-43 and promotes its aggregation [11]. Our results 
provide the first evidence for the relevance of CK1E in the 
human disease since its levels highly correlate with TDP-
43 phosphorylation status in sALS patients. The evidence 
that TDP-43 associates with CK1E at the protein level, and 
ectopic CK1E overexpression in iPSC-derived MNs leads to 
increased pTDP-43 accumulation, support that CK1E may 
be a candidate for therapeutic intervention.
In summary, we elucidated individual gene expression 
profiles in LCM-isolated MN pools using an unbiased 
methodology and correlated them with pTDP-43 pathology 
in an effort to characterize early molecular signatures in 
sALS. Since animal models of sporadic forms of MN dis-
eases do not yet exist, this approach focused on identifying 
disease features directly in human tissue. Using transcrip-
tome–pathology correlations, we uncover a disease-associ-
ated kinase regulating TDP-43 phosphorylation in MNs, and 
thus identify a candidate for further research and a potential 
therapeutic target to alleviate MN degeneration.
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